BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33982429)

  • 21. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.
    Stalker D; Reid S; Ramaiya A; Wisemandle WA; Martin NE
    Clin Ther; 2016 Aug; 38(8):1778-88. PubMed ID: 27473384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
    Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
    Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Safety Profile of DA-3803, a Proposed Biosimilar of Recombinant Human Chorionic Gonadotropin, in Healthy Subjects.
    Cha YJ; Kim KA; Oh TY; Park JY
    BioDrugs; 2015 Jun; 29(3):199-205. PubMed ID: 25998212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation.
    Richardson A; Sakariassen KS; Meyer JP; Alberts P; Sorensen AS
    Eur J Clin Pharmacol; 2013 Mar; 69(3):459-65. PubMed ID: 22815050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.
    Dillingh MR; van den Blink B; Moerland M; van Dongen MG; Levi M; Kleinjan A; Wijsenbeek MS; Lupher ML; Harper DM; Getsy JA; Hoogsteden HC; Burggraaf J
    Pulm Pharmacol Ther; 2013 Dec; 26(6):672-6. PubMed ID: 23380438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The comparative pharmacokinetics of modified-release and immediate-release paracetamol in a simulated overdose model.
    Chiew A; Day P; Salonikas C; Naidoo D; Graudins A; Thomas R
    Emerg Med Australas; 2010 Dec; 22(6):548-55. PubMed ID: 21143403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of a New Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
    Sikes CR; McMahen RL; Stark JG; Engelking D
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):29-35. PubMed ID: 28933918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.